Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Spatholobus suberectus* (SS), commonly known as Jixueteng in Traditional Chinese Medicine (TCM), is a botanical extract derived from the dried stems of the *Spatholobus suberectus* Dunn plant. Traditionally used to promote blood circulation and treat conditions such as anemia and menstrual irregularities, SS has gained attention for its potential antineoplastic properties. Research indicates that SS inhibits tumor cell proliferation by inducing apoptosis and arresting the cell cycle at the G2/M phase. This mechanism is associated with the induction of DNA damage and the subsequent activation of the Chk1 and Chk2 signaling pathways. Preclinical studies in breast cancer (MCF-7) and colon cancer (HT-29) models have demonstrated that SS effectively inhibits tumor growth in a dose-dependent manner, showing superior efficacy to docetaxel in xenograft models without significant systemic toxicity or weight loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on spatholobus suberectus.